Pac Premier
Giving Guide
You are here:  Home  >  Biotech  >  Current Article

Judge upholds Amgen’s Enbrel patents

By   /   Wednesday, July 1st, 2020  /   Comments Off on Judge upholds Amgen’s Enbrel patents

    Print       Email
Tri-county biotech heavyweight Amgen shot up more than 8 percent July 1 on news that it had successfully defended patents on bestselling rheumatoid arthritis drug Enbrel in a court contest with competitor Sandoz.  Shares of Thousand Oaks-based Amgen hit a new 52-week high and closed at $255.12.  The decision by the U.S. Court of Appeals…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Limoneira, Calavo both report earnings growth as produce industry continues recovery

Read More →